Management’s guidance upgrade for FY19
13/01/20 -"Given the strong uptake of Cimzia (33% of sales) and Vimpat (25% of sales) across geographies in Q4 19, we have upgraded our revenue estimates for the forecast years. Combined with robust operational ..."
Pages
50
Language
English
Published on
13/01/20
You may also be interested by these reports :
17/06/26
Our target price is reduced to CHF94 (from CHF97) on the back of a lower sales base. We have also adjusted forward years’ growth, slightly increasing ...
15/06/26
The target price is upgraded on the back of higher margins in 2026. The EBITDA margin is lifted from 15.4% to 17.9% for the full year (guidance is ...
09/06/26
Our estimates for 2026-2027 have been revised downward following the reclassification of Capsules & Health Ingredients (CHI) as discontinued ...
08/06/26
Anticipated sales are now even more skewed toward 2H, with HSD growth expected in 1H. We also record a CHF15m decrease in Building K sales in 2026, ...